Recovery of Bi-213 from an Ac-225 Cow: Application to the Radiolabeling of Antibodies with Bi-213

  • C. Greg Pippin
  • Otto A. Gansow
  • Martin W. Brechbiel
  • Lother Koch
  • R. Molinet
  • Jaques van Geel
  • C. Apostolidis
  • Maurits W. Geerlings
  • David A. Scheinberg

Abstract

Alpha particle-emitting radionuclides are among the most promising nuclides for the treatment of metastatic cancers.1 Because of their short range (60 to 100 μm) and high Linear Energy Transfer (LET) values, alpha-emitters can deliver a very large radiation dose over the distance of a few cell diameters. When alpha-emitters are linked to tumor seeking monoclonal antibodies (mAbs), the resulting product is a potentially powerful cancer therapeutic. Efforts are underway in many laboratories, including ours, to develop alpha-emitting mAb systems.

Keywords

Linear Energy Transfer Chelate Agent Transuranium Element High Linear Energy Transfer Bifunctional Chelate Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    T.A. Waldmann, Monoclonal Antibodies in Diagnosis and Therapy. Science. 252:1661 (1991).CrossRefGoogle Scholar
  2. 2.
    D.S. Wilber, Potenial Use of Alpha Emitting Radionuclides in the Treatment of Cancer, Antibody, Immunoconjugates and Radiopharmaceuticals. 4:85–97.Google Scholar
  3. 3.
    M.W. Brechbiel, C.G. Pippin, T.J. McMurry, D. Milenic, M. Roselli, D. Colcher, and O.A. Gansow, An Effective Chelating Agent for Labelling of Monoclonal Antibody with Bi-212 for α-Particle Mediated Radioimmunotherapy. J. Chem. Soc. Chem. Commun., 1169–1170 (1991).Google Scholar
  4. 4.
    R.B. Huneke, C.G. Pippin, R.A. Squire, M.W. Brechbiel, O.A. Gansow, and M. Strand, Effective α-Particle-mediated Radioimmunotherapy of Murine Leukemia. Cancer Res., 52:5818–5820 (1992).PubMedGoogle Scholar
  5. 5.
    M.W. Geerlings, Radionuclides for Radioimmunotherapy: Criteria for Selection. Int. Journ. Biol. Markers, in press.Google Scholar
  6. 6.
    M.W. Geerlings, F.M. Kaspersen, C. Apostolidis, and R. Van Der Hout, The Feasibility of Ac-225 as a Source of α-particles in Radioimmunotherapy, Nucl. Med. Commun. 14:121–125 (1993).Google Scholar
  7. 7.
    M.W. Geerlings, Radioimmunotherapy Using α-Particles Emission. Int. Patent WO 90/15625 (1990).Google Scholar
  8. 8.
    S. Mirzadeh, M. W. Brechbiel, R. W. Atcher, and O.A. Gansow, Radiolabeling of Immunoproteins: Covalent Linkage of 2-(4-Isothiocyanatobenzyl)diethylene-triaminepentaacetic Acid Ligands to Immunoglobulin. Bioconjugate Chem., 1:59–64 (1990).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • C. Greg Pippin
    • 1
  • Otto A. Gansow
    • 1
  • Martin W. Brechbiel
    • 1
  • Lother Koch
    • 2
  • R. Molinet
    • 2
  • Jaques van Geel
    • 2
  • C. Apostolidis
    • 2
  • Maurits W. Geerlings
    • 3
  • David A. Scheinberg
    • 4
  1. 1.Chemistry Section, Radiation Oncology Branch, National Cancer InstituteNIHBethesdaUSA
  2. 2.European Institute for Transuranium ElementsKarlsruheGermany
  3. 3.Alphamedical Holdings B.V.AmsterdamThe Netherlands
  4. 4.Sloan-Kettering InstituteMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations